Tate & Lyle Ventures and Agri Investment Fund have co-led a 3.5m investment into Fugeia, a newly formed functional food technology business with a focus on gut health.
| Revenue (Most Recent Fiscal Year) | $2.21B |
| Net Income (Most Recent Fiscal Year) | $182.45M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.09 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 5.27 |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | 2.19 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.24 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.73 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $18.19 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 111.36M |
| Free Float | 111.19M |
| Market Capitalization | $2.27B |
| Average Volume (Last 20 Days) | 2017.60 |
| Beta (Past 60 Months) | 0.28 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.15% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.64 |
| Dividend Yield (Based on Last Quarter) | 3.15% |